๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for SSc-Systemic Sclerosis

Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies NCT01776398n/a1 site๐Ÿ“ New York Weill Medical College of Cornell University A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis. NCT07641634Phase 1, Phase 213 sites๐Ÿ“ Melbourne๐Ÿ“ Beijing๐Ÿ“ Guangzhou Prolium Bioscience, Inc ยท Tests: PRO-203, Placebo Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy NCT07493395Phase 24 sites๐Ÿ“ Lille๐Ÿ“ Montpellier๐Ÿ“ Paris University Hospital, Montpellier ยท Tests: CD19 CAR T Arm Rare AutoImmune SElf-management Programme Development NCT06642870n/a1 site๐Ÿ“ Bristol University of the West of England ยท Tests: Non-interventional study CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases NCT06941129Phase 11 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: UCAR T-cell A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis NCT07497087Phase 3248 sites๐Ÿ“ Birmingham๐Ÿ“ Phoenix๐Ÿ“ Scottsdale Boehringer Ingelheim ยท Tests: Placebo matching nerandomilast formulation 1, Placebo matching nerandomilast formulation 2, Nerandomilast formulation 1โ€ฆ Safety and Efficacy of Adipose-Derived Regenerative Cells (ADRCs) for Improving Hand Dysfunction in Systemic Sclerosis NCT07360808NA2 sites๐Ÿ“ Guangzhou๐Ÿ“ Shanghai Cytori Therapeutics ยท Tests: Autologous ADRCs injection Combined with Standard Therapy, Standard Treatment group Safety and Efficacy of Universal CD19-targeting CAR-ฮณฮดT Cells in Refractory Autoimmune Diseases NCT06828042Phase 1, Phase 21 site๐Ÿ“ Beijing Peking University Third Hospital ยท Tests: anti-CD19 CAR T cell therapy CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases NCT07315087Phase 11 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: QT-019C Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSC NCT07355972EARLY Phase 11 site๐Ÿ“ Wuhan Union Hospital, Tongji Medical College, Huazhong Universityโ€ฆ ยท Tests: CAR-T Therapy The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life NCT06675344NA4 sites๐Ÿ“ New Orleans๐Ÿ“ Ann Arbor๐Ÿ“ Pittsburgh Robyn T. Domsic, MD, MPH ยท Tests: Apollo Neuro Device, Sham device BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases NCT06794008Phase 21 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: BCMA-CD19 CAR-T therapy Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis NCT06954597Phase 26 sites๐Ÿ“ Bordeaux๐Ÿ“ La Tronche๐Ÿ“ Lille Topadur Pharma AG ยท Tests: TOP-N53, Sildenafil, TOP-N53 vehicle The Effect of Progressive Muscle Relaxation Exercises on Fatigue, Dyspnea, and Respiratory Function in Patients With Systemic Sclerosis NCT07842133NA1 site๐Ÿ“ Gaziantep University of Gaziantep ยท Tests: Progressive Muscle Relaxation Exercise CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease NCT07305116Phase 11 site๐Ÿ“ Hangzhou The Children's Hospital of Zhejiang University School of Meโ€ฆ ยท Tests: UCAR T-cell A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease NCT06189495Phase 24 sites๐Ÿ“ Beijing๐Ÿ“ Wuhan๐Ÿ“ Jinan Changchun GeneScience Pharmaceutical Co., Ltd. ยท Tests: GenSci048, GenSci048 placebo Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases NCT07184450Phase 11 site๐Ÿ“ Hangzhou Chongqing Precision Biotech Co., Ltd ยท Tests: BCMA/CD70-targetd CAR-T A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases NCT06978647Phase 11 site๐Ÿ“ Beijing China Immunotech (Beijing) Biotechnology Co., Ltd. ยท Tests: YTS109 cell A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases NCT07167537Phase 11 site๐Ÿ“ Beijing Beijing GoBroad Hospital ยท Tests: OL-CD19-GDT Multicenter Study on the Development of Pulmonary Arterial Hypertension Screening Models Based on Artificial Intelligence for Patients With Systemic Sclerosis NCT07236970n/a5 sites๐Ÿ“ Granada๐Ÿ“ Santander๐Ÿ“ Barcelona Alejandro Cruz Utrilla Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases NCT07085676Phase 11 site๐Ÿ“ Jerusalem Polina Stepensky ยท Tests: HBI0101 CART Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients NCT07249060n/a1 site๐Ÿ“ Pamplona Hospital Universitario Araba ยท Tests: Immune Checkpoint Inhibitors A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease NCT05878717Phase 2, Phase 3134 sites๐Ÿ“ Phoenix๐Ÿ“ Scottsdale๐Ÿ“ Scottsdale GlaxoSmithKline ยท Tests: Belimumab, Placebo Home-Based Clinical Management of Cardiac Complications in Systemic Sclerosis NCT06865118n/a1 site๐Ÿ“ Oslo Oslo University Hospital Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders NCT06434363Phase 1, Phase 22 sites๐Ÿ“ Houston๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Tafasitamab, Fludarabine phosphate, Cyclophosphamide, Tafasitamab and NK cells AlloNKยฎ, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. NCT06991114Phase 252 sites๐Ÿ“ Tuscaloosa๐Ÿ“ Phoenix๐Ÿ“ Tucson Artiva Biotherapeutics, Inc. ยท Tests: Allogeneic NK Cells A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease NCT06308978Phase 121 sites๐Ÿ“ Beverly Hills๐Ÿ“ Fullerton๐Ÿ“ Irvine Fate Therapeutics ยท Tests: FT819, Fludarabine, Cyclophosphamide, Bendamustine Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease NCT07507201EARLY Phase 11 site๐Ÿ“ Hangzhou The Children's Hospital of Zhejiang University School of Meโ€ฆ ยท Tests: UCAR T-cell Cultural Adaptation, Validity, and Reliability of the Turkish Version of The PASTUL Questionnaire NCT07182968n/a1 site๐Ÿ“ ร‡ankaya Hacettepe University ยท Tests: Questionnaire study A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases NCT07115745Phase 128 sites๐Ÿ“ Boston๐Ÿ“ Durham๐Ÿ“ Camperdown Juno Therapeutics, Inc., a Bristol-Myers Squibb Company ยท Tests: BMS-986515, Fludarabine, Cyclophosphamide, Tocilizumab
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy